United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications

C. Gregory Elliott, Eric D. Austin, David Badesch, Jessica Badlam, Raymond L. Benza, Wendy K. Chung, Harrison W. Farber, Kathy Feldkircher, Adaani E. Frost, Abby D. Poms, Katie A. Lutz, Michael W. Pauciulo, Chang Yu, William C. Nichols

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Diagnostic World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) and Diagnostic Group 1' pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) are progressive and fatal disorders. Past registries provided important insights into these disorders, but did not include hormonal exposures or genomic data. The United States Pulmonary Hypertension Scientific Registry (USPHSR) will provide demographic, physiologic, anorexigen and hormone exposure, genomic, and survival data in the current therapeutic era for 499 patients diagnosed with PAH, PVOD, or PCH. The USPHSR also will explore the relationship between pharmacologic, non-pharmacologic, and dietary hormonal exposures and the increased risk for women to develop idiopathic or heritable PAH.

Original languageEnglish (US)
JournalPulmonary Circulation
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2019

Keywords

  • Phenotype
  • genotype
  • hormones
  • pulmonary hypertension
  • toxins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications'. Together they form a unique fingerprint.

Cite this